

# JCEM




THE JOURNAL  
OF CLINICAL  
ENDOCRINOLOGY  
& METABOLISM

## Why Is Androgen Replacement in Males Controversial?

Glenn R. Cunningham and Shivani M. Toma

J. Clin. Endocrinol. Metab. 2011 96:38-52 originally published online Sep 29, 2010; , doi: 10.1210/jc.2010-0266

To subscribe to *Journal of Clinical Endocrinology & Metabolism* or any of the other journals published by The Endocrine Society please go to: <http://jcem.endojournals.org/subscriptions/>



## Why Is Androgen Replacement in Males Controversial?

Glenn R. Cunningham and Shivani M. Toma

Baylor College of Medicine and St. Luke's Episcopal Hospital, Houston, Texas 77030

**Context:** Symptoms and signs consistent with androgen deficiency and low testosterone levels are recognized frequently in clinical practice. Recent population-based epidemiological studies indicate that low testosterone levels in men are associated with increased morbidity and mortality. The clinician must be able to counsel patients to help them determine whether testosterone replacement therapy is appropriate for them.

**Evidence Acquisition:** The authors have conducted a literature search in PubMed, and we have reviewed references in the multiple systematic reviews and meta-analyses that have been published on this topic.

**Evidence Synthesis:** We have attempted to provide the reader with an appreciation of the evidence that can be used to support the diagnosis of androgen deficiency, the efficacy of treatment, the potential risks of treatment, the therapeutic options, and the recommendations for monitoring treatment.

**Conclusions:** We think that published clinical experience justifies testosterone replacement therapy in males who have not initiated puberty by age 14 and in males with low testosterone levels due to classical diseases of the hypothalamic-pituitary-gonadal axis. The benefit:risk ratio is less certain in older men and in those with chronic diseases associated with low testosterone levels. The decision to treat in this setting is much more controversial because there are few large clinical trials that have demonstrated efficacy and no large clinical trials that have determined potential risks of increasing the incidence of clinical prostate cancers or cardiovascular events. We provide a critical review of the evidence that supports treatment and potential risks and ways to reduce the risks if the physician and patient elect testosterone replacement. (*J Clin Endocrinol Metab* 96: 38–52, 2011)

**E**valuation and treatment of males suspected of having testosterone deficiency entails multiple controversial issues. Recognition of the high prevalence of low testosterone levels in many men with common chronic diseases, an aging population, and greater recognition that testosterone levels fall with aging have greatly expanded the number of men who are diagnosed to have low testosterone levels. The development of new delivery systems and increased marketing of these delivery systems have combined with the larger number of potential patients to make testosterone replacement more common. It is a hot topic for the lay press and primary care clinicians, as well as for urologists and endocrinologists.

Modern medicine is striving to provide evidence-based care. To do this we need large, randomized, placebo-controlled trials (RPCTs), preferably multicentered, and preferably government funded. Treatment of testosterone deficiency due to classical diseases affecting the hypothalamus, pituitary, and/or testes has been accepted for decades, although there were no multicenter trials. Some of the testosterone delivery systems predate the requirement for multicenter studies, and most of the more recently developed testosterone delivery systems were approved by the Food and Drug Administration on the basis of their pharmacokinetic profile and their ability to achieve physiological blood levels. Approval was not

ISSN Print 0021-972X ISSN Online 1945-7197

Printed in U.S.A.

Copyright © 2011 by The Endocrine Society

doi: 10.1210/jc.2010-0266 Received February 2, 2010. Accepted August 24, 2010.

First Published Online September 29, 2010

For editorial see page 62

Abbreviations: BMD, Bone mineral density; CI, confidence interval; HDL, high-density lipoprotein; HPG, hypothalamic-pituitary-gonadal; PSA, prostate-specific antigen; RPCT, randomized, placebo-controlled trial.

based on long-term studies of efficacy and risk. Some outcome studies have provided sufficient data to permit meta-analyses. However, most of these analyses have relied on a limited number of small clinical trials of short duration, and they have used a variety of testosterone delivery systems. Thus, their conclusions often are compromised. This review will identify many of the issues that continue to challenge clinicians, investigators, and patients. This is even truer for most busy primary care clinicians who write a large percentage of the prescriptions for testosterone treatment.

## Epidemiology

Cross-sectional and longitudinal population-based studies have evaluated the prevalence of low testosterone levels, and some of them have used questionnaires to evaluate associated symptoms. The Baltimore Longitudinal Study of Aging found low total testosterone levels in approximately 20% and low free testosterone index levels in approximately 35% of men 60–69 yr of age (1). Low testosterone levels were much more prevalent in older age groups. In the Massachusetts Male Aging Study, total testosterone levels declined cross-sectionally at 0.8%/yr of age, whereas both free and bioavailable testosterone levels declined at about 2%/yr of age (2). The longitudinal decline for subjects between baseline and follow-up was 1.6%/yr for total testosterone and 2–3%/yr for bioavailable testosterone. A cross-sectional survey of 3200 community-dwelling men aged 40–79 yr from a prospective cohort study in eight European countries found an age-related decrease in calculated free testosterone levels of 9 pg/dl · yr (3). The prevalence of symptomatic hypogonadism increases with age, especially after age 70 (4). The Boston Area Community Health survey of men 40–70 yr of age at baseline did not find significant differences in the prevalence of testosterone deficiency among non-Hispanic whites, Hispanics, and African-Americans (5).

Until recently, it was thought that testosterone deficiency in middle-aged and older men mainly affected the quality of life, but it was unlikely to affect morbidity or mortality. However, population-based studies indicate that testosterone deficiency predicts future development of type 2 diabetes mellitus (6), metabolic syndrome (7), cardiovascular events (8–11), mobility limitation (12), frailty (13), and mortality (8–11). Whether testosterone treatment can improve health and prolong active lifestyles is unknown. No large, multicenter, long-term RPCTs have addressed these issues.

## Diagnosis

### Definition of hypogonadism

The Endocrine Society's Clinical Practice Guideline for Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes has defined hypogonadism in men as “a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone (androgen deficiency) and a normal number of spermatozoa due to disruption of one or more levels of the hypothalamic-pituitary-gonadal (HPG) axis” (14).

### Symptoms and signs associated with classical causes of hypogonadism

The Endocrine Society Guidelines Committee identified signs and symptoms that are more suggestive of androgen deficiency (14). They include incomplete sexual development, reduced libido, decreased spontaneous erections, breast discomfort or gynecomastia, loss of body hair or reduced shaving, very small or shrinking testis, inability to father children or low sperm counts, decreased bone mineral density (BMD) and osteoporosis, decreased muscle mass and strength, and hot flashes. Other manifestations that are associated with androgen deficiency but are less specific include decreased energy and motivation, dysthymia, decreased intellectual capacity, poor concentration, depression, fatigue, sleep disturbance, mild anemia (normochromic, normocytic, in the female range), increased body fat, increased body mass index, and diminished physical performance (14). The less specific symptoms and signs can be caused by other conditions, and comorbidities make the diagnosis more difficult in older men.

Zitzmann *et al.* (15) surveyed 434 consecutive male patients aged 50–86 yr in an andrological outpatient department to determine whether psychosomatic complaints and metabolic factors were related to sex hormone levels in a symptom-specific manner. No clear-cut threshold for late-onset hypogonadism was found. Rather, prevalence of psychosomatic symptoms and metabolic risk factors increased with decreasing androgen levels. The prevalence of loss of libido or vigor increased with testosterone concentrations less than 432 ng/dl, and depression and type 2 diabetes mellitus were more common in men with testosterone concentrations less than 288 ng/dl. Testosterone concentrations below 230 ng/dl contributed to erectile dysfunction.

Using the large European Male Ageing Study database of 3369 men between the ages of 40 and 79, Wu *et al.* (16) have found that poor morning erections, low sexual desire, erectile dysfunction, inability to perform vigorous activity, depression, and fatigue were significantly related to the testosterone level. They found that late-onset hy-

hypogonadism can be defined by the presence of at least three sexual symptoms associated with a total testosterone of less than 320 ng/dl and a free testosterone less than 6.5 ng/ml. The three sexual symptoms had a syndromic relationship with decreased testosterone levels.

### Questionnaires

Questionnaires can help patients and clinicians recognize medical conditions. Lack of specificity has been the greatest problem with existing questionnaires used to detect hypogonadism, and lack of sensitivity of these questionnaires is an issue in assessing treatment (14). A new screening questionnaire has been developed that promises greater specificity (17). However, it has not been used in large populations, and it is not known whether it will be useful in assessing testosterone treatment.

### Laboratory diagnosis

The diagnosis of testosterone deficiency requires the presence of symptoms and low serum testosterone levels, but the normal ranges for different assays vary greatly. It is well recognized that serum testosterone levels exhibit a diurnal pattern in younger men, with higher levels in the early morning (18). The diurnal pattern is blunted in most older men (18, 19). Thus, sampling time is important because normal ranges are based on early morning sampling in younger healthy men. The Endocrine Society appointed a task force to address issues related to sensitivity, variability, and standardization of testosterone assays (20). They have stated that “laboratory proficiency testing should be based on the ability to measure accurately and precisely samples containing known concentrations of testosterone, not only in agreement with others using the same method.”

One should recognize factors that affect SHBG levels and thus total testosterone levels and know techniques used to estimate bioavailable or free testosterone levels. SHBG concentrations are decreased in patients with moderate to severe obesity, nephrotic syndrome, hypothyroidism, acromegaly, and in those who are taking glucocorticoids, progestins and androgenic steroids. SHBG levels are increased with aging and in patients with cirrhosis, hepatitis, hyperthyroidism, or HIV disease, and in those men who are taking anticonvulsants or estrogens (14).

Total testosterone levels are now being measured by liquid chromatography-tandem mass spectrophotometer in large reference laboratories and in some research laboratories (21). Liquid chromatography-tandem mass spectrophotometer provides greater accuracy than either platform assays or RIAs because it does not encounter issues of cross-reactivity. However, the equipment is ex-

pensive, so this methodology is not available in smaller regional and hospital laboratories. Until recently, there was no effort to use a common standard for testosterone assays. Under the leadership of the Centers for Disease Control (CDC), there is a national effort to correct this problem (20, 21). Although there is some uncertainty as to how best to estimate testosterone concentrations that are available to peripheral tissues, determination of free testosterone by equilibrium dialysis has been the gold standard (22). Because equilibrium dialysis requires greater technical expertise, time, and cost, it is not a practical test for most laboratories. Many think that both albumin-bound testosterone and unbound testosterone are available to peripheral tissues. Bioavailable (free and albumin-bound) testosterone can be assayed after ammonium sulfate precipitation of SHBG-bound testosterone (23). Vermeulen *et al.* (22) have popularized the use of calculated free testosterone and calculated bioavailable testosterone measurements based on measuring total testosterone, SHBG, and albumin and then using a mass action equation. These values correlate well with those obtained by equilibrium dialysis or by actual measurement of bioavailable testosterone, but it requires accurate measurement of total testosterone and SHBG. Furthermore, there are different equations, which give somewhat different results (24). Finally, normal ranges using this approach are not readily available. Unlike the preceding techniques to measure or estimate free testosterone, the direct measurement of free testosterone by RIA does not provide valid results when there are alterations in SHBG (22). This technique should not be used! Thus, whereas there have been improvements in assaying total, bioavailable, and free testosterone levels, uncertainties remain. Hopefully, the effort undertaken by the CDC will lead to much more accurate assays, better standardization of assays, and the establishment of similar normal ranges.

It is important to determine whether the patient has primary or secondary hypogonadism. To do this, one must measure serum LH, and prolactin should be assayed in patients with secondary hypogonadism to identify the rare patient who has a prolactinoma. The majority of men who do not have a classical cause of hypogonadism will have low testosterone levels and low or inappropriately normal LH and FSH levels. The Endocrine Society Guidelines recommend imaging the hypothalamus and pituitary only if there are other findings suggesting hypothalamic or pituitary disease or if the total testosterone level is below 150 ng/dl. This recommendation is based on one report of 164 men 27 to 79 yr of age whose chief complaint was erectile dysfunction and who had serum testosterone levels less than 230 ng/dl and low or inappropriately normal LH levels (25). Macroadenomas and hypothalamic lesions

**TABLE 1.** Testosterone replacement RPCTs in men 20–80 yr of age

First author, year (Ref.)	n (T/P)	Age (yr)	T criteria (ng/dl)	TRT	Duration (months)	Outcomes
Sih, 1997 (70)	22 (10/12)	≥50	Bioavailable T < 60	TC im	12	↑ Strength, ↑ hemoglobin, no change in memory
Steidle, 2003 (122)	406 (307/99)	20–80	T < 300	T gel, 50 and 100 mg/d; T patch, two 2.5 mg/d	6	↑ Body composition, ↑ libido, ↑ hematocrit
Merza, 2006 (123)	38 (20/18)	>40	T < 288 or FAI < 30% <sup>a</sup>	T patch, 5 mg/d	6	↓ FM, ↑ hemoglobin; no change LBM, BMD, or markers of bone turnover
Brockenbrough, 2006 (124)	40 (19/21)	≥18	T ≤ 300	T gel, 10 g/d	6	No change lipids, body composition, sexual function, or BMD
Marks, 2006 (125)	44 (22/22)	44–78	T < 300	TE im, 150 mg every 2 wk	6	No change prostate tissue androgens, cellular function, or gene expression; ↑ hematocrit
Chiang, 2009 (126)	30 (15/15)	20–75	T < 300 or free T < 8.7	T gel, 5g/d	3	↑ Erectile function, no change in libido
Shores, 2009 (65)	33	≥50	T ≤ 280	T gel, 7.5 g/d	3	↓ Subthreshold depression
Legros, 2009 (115)	322	≥50	Free T < 7.5	Oral TU, 80, 160, or 240 mg/d	12	↑ Sexual domain of AMS <sup>b</sup> but only with 160 mg/d

We only included parallel studies of 3 months or longer and men with baseline testosterone levels less than 300 ng/dl (<10.4 nmol/liter), bioavailable testosterone levels less than 150 ng/dl (<5.2 nmol/liter), or free testosterone levels less than 9.0 ng/dl (<0.31 nmol/liter). n (T/P), Total number of men included in trial (number of men treated with testosterone therapy/number of men treated with placebo); TRT, type of testosterone replacement therapy used in the trial; T, testosterone; TC, testosterone cypionate; TE, testosterone enanthate; TU, testosterone undecanoate; FFM, fat-free mass; FM, fat mass; LBM, lean body mass. To convert nanograms per deciliter to nanomoles per liter, multiply by 0.0347.

<sup>a</sup> Free androgen index (FAI), which is total T/SHBG × 100.

<sup>b</sup> Aging Males' Symptoms (AMS) rating scale.

were confined to six subjects with testosterone levels of 104 ng/dl or less. Assessment of the karyotype to diagnose Klinefelter's syndrome is recommended for those men with a testicular volume less than 4 ml, low testosterone levels, and elevated LH levels (26, 27).

Most middle-aged and older men with symptoms consistent with hypogonadism and low testosterone levels will have one or more chronic diseases, and many of these men are obese. The majority of these men will have functional abnormalities of the HPG axis rather than anatomical or congenital abnormalities. Whether their symptoms are due to the comorbid condition or to the low testosterone levels is the question. The majority of these men will increase their serum LH and testosterone levels when treated with clomiphene citrate (28). We interpret this response to indicate that the abnormality is functional. One also frequently observes low total and sometimes free testosterone levels in men with moderate or severe obesity. When obese patients lose significant weight, their serum testosterone levels usually increase (29, 30). This provides further support for functional abnormalities of the HPG axis in many of these men.

## Clinical Trials

### Age considerations

We think that age must be considered when deciding to prescribe and monitor testosterone treatment. Studies that have included men 20 yr of age and older are listed in Table 1. We only included parallel studies of 3 months or longer and men with baseline testosterone levels below 300 ng/dl, bioavailable testosterone levels below 150 ng/dl, or free testosterone levels below 9.0 ng/dl. The total and free testosterone cutoffs are those recommended by The Endocrine Society Clinical Practice Guideline (14), and the bioavailable testosterone cutoff is that proposed by Vermeulen (31) and endorsed by The Endocrine Society Position Statement (20). Comorbid diseases may make older patients less responsive to testosterone replacement, so a separate table lists studies that were limited to men 60 and older (Table 2). Because SHBG levels increase with age, we have included studies with total testosterone levels below 350 ng/dl. We recognize that there are many informative trials that have included men with higher cutoffs and several relatively large studies that do not meet our inclusion criteria but may provide efficacy information (32–36); however, these trials are at greater risk of failure to dem-



**TABLE 2.** Testosterone replacement RCTs in men age 60 yr or older

First author, year (Ref.)	n (T/P)	Age (yr)	T criteria (ng/dl)	TRT	Duration (months)	Outcomes
Kenny, 2001 (78)	44 (24/20)	>65	Bioavailable T < 128	T patch, two × 2.5 mg/d	12	↓ Bone loss at femoral neck, ↑ FFM, ↓ FM, no change in lower extremity strength
Kenny, 2002 (71)	44 (24/20)	>65	Bioavailable T < 128	T patch, 2–2.5 mg/d	12	No change cognition
Tan, 2003 (66)	10 (5/5)	68–80	T < 240	TE im, 200 mg every 2 wk	12	↑ Cognition
Cavallini, 2004 (61)	130 (40/45/45) <sup>a</sup>	>60	Free T < 6 pg/ml	Oral TU, 160 mg/d	6	↑ Erectile function, libido, mood, and vitality
Kenny, 2004 (63)	11 (6/5)	73–87	Bioavailable T < 128	TE im, 200 mg every 3 wk	12	No change in mood or cognition
Amory, 2004 (79)	50 (17/18/15) <sup>b</sup>	65–83	T < 350	TE im, 200 mg every 2 wk; or TE + finasteride 5 mg/d <sup>c</sup>	36	↑ BMD lumbar vertebrae and hip, ↑ hematocrit
Page, 2005 (127)	50 (17/18/15) <sup>b</sup>	65–83	T < 350	TE im, 200 mg every 2 wk; or TE + finasteride, 5 mg/d <sup>c</sup>	36	↑ Hand grip strength, ↑ FFM, ↓ FM, ↑ physical function
Nair, 2006 (128)	87 (27/29/31) <sup>d</sup>	≥60	Bioavailable T < 103	T patch, 5 mg/d	24	↑ FFM, no change strength, no change QOL, ↑ BMD femoral neck
Vaughan, 2007 (129)	69 (24/23/22) <sup>b</sup>	≥65	T < 350	TE im, 200 mg every 2 wk; or TE + finasteride, 5 mg/d <sup>c</sup>	36	No change cognition
Agledahl, 2008 (130)	26 (13/13)	60–80	T < 317	TU im, 1000 mg every 6–12 wk	12	No change lipids or lipase activity, ↑ FFM, ↓ FM
Basurto, 2008(131)	48 (25/23)	≥60	T ≤ 320	TE im, 250 mg every 3 wk	12	↑ Lumbar BMD
Svartberg, 2008 (132)	35 (17/18)	60–80	<317	TU im, 1000 mg every 6–12 wk	12	↑ FFM, ↓ FM, ↑ hip BMD, ↑ handgrip strength, ↑ hemoglobin and hematocrit; no change weight, glucose, lipids, knee extension, QOL, or cognition
Agledahl, 2009 (133)	26 (13/13)	60–80	<317	TU im, 1000 mg every 6–12 wk	12	No change in tissue factor coagulation or in tissue factor pathway inhibitor
Srinivas-Shankar, 2010 (64)	274 (138/136)	≥65	T < 345 or free T < 7.2	T gel, 5 g/d <sup>c</sup>	6	↑ FFM, ↓ FM, ↑ strength, ↑ physical function and sexual domain of AMS, <sup>e</sup> ↑ QOL
Basaria, 2010 (82)	106/103	≥65	T < 350 or free T < 5.0	T gel, 10 g/d <sup>c</sup>	6	Study stopped early; ↑ cardiac, dermatological and respiratory events; ↑ leg-press and chest-press strength; ↑ stair-climbing power with load

Because SHBG levels increase with age, we have included men with total testosterone levels less than 350 ng/dl (<12.3 nmol/liter), bioavailable testosterone levels less than 150 ng/dl (<5.2 nmol/liter), or free testosterone levels less than 9.0 ng/dl (<0.31 nmol/liter). n (T/P), Total number of men included in trial (number of men treated with testosterone therapy/number of men treated with placebo); TRT, type of testosterone replacement therapy used in the trial; T, testosterone; TC, testosterone cypionate; TE, testosterone enanthate; TU, testosterone undecanoate; FFM, fat-free mass; FM, fat mass; QOL, quality of life. To convert nanograms per deciliter to nanomoles per liter, multiply by 0.0347.

<sup>a</sup> Testosterone/placebo/carnitine treatment arms.

<sup>b</sup> Testosterone/placebo/testosterone + finasteride.

<sup>c</sup> Then dose adjusted.

<sup>d</sup> Testosterone/dehydroepiandrosterone/placebo.

<sup>e</sup> Aging Males' Symptoms (AMS) rating scale.

onstrate efficacy of testosterone treatment because they included eugonadal men. Values above 350 ng/dl do not require substitution, according to the recommendations of International Society of Andrology, International Society for the Study of Aging Male, European Association of Urology, European Academy of Andrology, and American Society of Andrology (37). There also are several relatively large phase III trials that have not been placebo controlled but have used another testosterone delivery system for comparison (38–41). Some open-label trials have compared long-acting injectable testosterone undecanoate with testosterone enanthate or a testosterone gel (42). These trials also provide considerable useful information. Finally, most testosterone trials can provide useful information regarding potential side effects; however, no trial has been powered to assess the potential risk that testosterone replacement will increase clinical prostate cancers or cardiovascular events.

### **Ages 14–19 yr**

Most endocrinologists consider testosterone treatment if puberty has not been initiated spontaneously by age 14 (43). When sexual development is delayed, it can cause psychological problems, and it may reduce adult bone mass (44). Whether chronic testosterone treatment will be required is dependent on factors that include the underlying cause for the testosterone deficiency, age, and desire for fertility in the near future. We are unaware of any RPCTs evaluating testosterone treatment in boys with constitutional delayed puberty, isolated gonadotropin deficiency, Klinefelter's syndrome, or prepubertal or pubertal acquired causes of hypogonadism. Testosterone can cause pubertal changes, and these changes usually are desirable in this setting. Most clinicians use injectable testosterone cypionate or enanthate, and effective dosing regimens have been developed (45). Transdermal testosterone gel can be used; however, it is more difficult to titrate to the desired dose and to ensure compliance. Human chorionic gonadotropin or recombinant human LH can be used in boys with hypogonadotropic hypogonadism, but these regimens are more expensive and they require greater patient compliance (46, 47). Pulsatile GnRH treatment also can be effective, but it is more cumbersome and more expensive (48). Unlike testosterone treatment, these treatments increase testicular size as well as testosterone levels. This may be of psychological benefit, and there could be benefit to future fertility. Although testosterone treatment can cause suppression of spermatogenesis, development of gynecomastia, and less commonly premature closure of the epiphyses, strategies for managing or preventing these conditions usually are effective.

### **Ages 20–49 yr**

Testosterone treatment for hypogonadal men between the ages of 20 and 49 also is effective and is associated with a low frequency of serious adverse events. Many of the men in this age range will have a congenital or acquired disease or condition that is known to impair one or more components of the HPG axis. An example of the benefits of treating men with such abnormalities is the study of Snyder *et al.* (49). They treated 18 previously untreated men who were 18 yr of age or older and who developed acquired hypogonadism after having gone through puberty. Their mean  $\pm$  SD serum testosterone was  $78 \pm 77$  ng/dl, and they were treated for up to 3 yr. There were striking improvements in energy, sexual function, body composition, bone density, and hematocrit. No serious side effects were reported, but prostate volume did increase. Some of the RPCTs have included some men in this age group (Table 1).

Testosterone treatment is not appropriate for the men with hypogonadotropic hypogonadism who seek fertility. Most of these men will require gonadotropin or pulsatile GnRH treatment (48, 50, 51). A few may respond to an antiestrogen (clomiphene citrate or tamoxifen) (52). Whereas testosterone treatment will suppress the HPG axis, these agents stimulate both testosterone secretion and spermatogenesis.

### **Ages 50–60 yr**

Several common chronic diseases including obesity, type 2 diabetes, and several inflammatory conditions are associated with low testosterone levels and are common in middle-aged and older men. They can be associated with symptoms suggesting androgen deficiency. Aging *per se*, without apparent comorbidity, also is associated with symptoms and low testosterone levels in some men in this age group. Most investigator-initiated as well as phase II and phase III clinical trials have included men more than 50 yr of age (Table 1).

### **Age 60 and older**

Several investigators have attempted to determine whether aging impairs tissue response to testosterone. The studies of Bhasin and colleagues (53–57) and those of Sattler *et al.* (57) provide some of the most convincing data showing that several organ systems of older men are responsive to testosterone treatment.

Several single-center RPCTs have been conducted in men 60 and older (Table 2). Most of the men in these studies did not have known anatomical disease involving the HPG axis, and many of them had comorbid conditions that could have been responsible for their symptoms and low testosterone levels. An Institute of Medicine panel recommended additional studies to know whether testosterone replacement therapy is beneficial for older men

with low testosterone levels. Based on these recommendations, The National Institute of Aging has funded The Testosterone Trial (<http://www.clinicaltrials.gov/ct2/show/NCT00799617>). This is a 1-yr, multicenter RPCT of men 65 yr of age and older. To qualify for the trial, men must complain of mobility issues, decreased libido, and/or decreased vitality, and they must have testosterone levels of less than 275 ng/dl. This study also will assess the effects of testosterone replacement on cognition, anemia, and several cardiovascular measures.

### Potential benefits of testosterone replacement

Increasing serum testosterone levels to the mid-normal range for a young male with testosterone replacement therapy has been proposed to improve libido, erectile function, mood, cognition, vitality, body composition, strength, mobility, type 2 diabetes, metabolic syndrome, some cardiovascular risk factors, anemia, and BMD. Usually, we do not treat men with low testosterone levels who are acutely ill or acutely stressed.

### Sexual function, libido, and erectile function

Several RPCTs have shown benefits of testosterone therapy on some aspects of sexual function. Two meta-analyses analyzed the effects of testosterone on different domains of sexual function (58, 59). Testosterone treatment moderately improved the number of nocturnal erections, sexual thoughts and motivation, number of successful intercourses, scores of erectile function, and overall sexual satisfaction in men with baseline testosterone levels below 346 ng/dl. Several of the trials shown in Tables 1 and 2 have reported benefits of testosterone treatment on sexual function. Most consistently, there have been more positive effects on libido than on erectile function.

### Mood and energy

Some RPCT studies have found that testosterone treatment improved mood, but others have not (60–64). In a meta-analysis reviewing the effects on depression, testosterone therapy was found to have beneficial effects on mood (60, 65), especially in patients with hypogonadism and HIV/AIDS. Some studies have found that testosterone treatment improved symptom scores in older men (Table 2) (61, 64).

### Cognition

Small RPCTs have reported mixed results on cognition. Some studies found benefit even in men with mild cognitive deficits or memory disorders such as Alzheimer's disease (66). Testosterone administration has been shown to improve spatial ability (67), verbal fluency (68), and

working memory (69) in elderly men, but other studies did not observe beneficial changes (34, 63, 70, 71). Most of these studies have included relatively small numbers of men, and treatment has been short-term.

### Body composition, muscle mass, and strength

The studies shown in Tables 1 and 2 that have assessed body composition have found significant changes. A meta-analysis concluded that testosterone therapy decreased fat mass and increased lean body mass with no overall change in body weight (72). These changes were noted both in men with baseline testosterone levels that averaged less than 300 ng/dl and in a larger number of studies in which the average baseline was considerably greater than 300 ng/dl. The effects of testosterone on muscle strength were heterogeneous, showing a tendency toward improvement only with leg/knee extension and handgrip of the dominant arm. Effects on physical function also have been inconsistent, and few trials have included men with functional limitations.

### Metabolic syndrome and type 2 diabetes mellitus

Several clinical trials have been conducted to determine whether testosterone treatment will improve glucose control. Some small studies have found improvement in hemoglobin A1c and/or homeostasis model of assessment for insulin resistance (73–75). However, an unpublished, multicenter RPCT funded by Solvay Pharmaceuticals failed to demonstrate significant changes in homeostasis model of assessment for insulin resistance or hemoglobin A1c, although there was a significant increase in lean body mass in men treated with testosterone gel (<http://www.solvaypharmaceuticals.com/static/wma/pdf/1/3/4/4/2/S176.2.101.pdf>).

### Bone mineral density

Fink *et al.* (76) reported that the prevalence of osteoporosis in hypogonadal males was twice that of men with normal testosterone levels (6 vs. 2.8%). Two meta-analyses of RPCTs showed a moderate increase in lumbar BMD in men and inconclusive results on femoral neck BMD (72, 77). Studies in Table 2 of 12 months or longer found that testosterone treatment improved BMD (78, 79). No fracture studies have been reported.

### Potential risks of testosterone replacement

The potential risks of testosterone replacement include acne; worsening of male pattern baldness; gynecomastia; precipitating or worsening of sleep apnea; increasing benign prostatic hyperplasia; and increasing lower urinary tract symptoms, causing an occult prostate cancer to become a clinical prostate cancer, accelerating the growth of



metastatic prostate cancer, accelerating the growth of a breast cancer, suppressing spermatogenesis, erythrocytosis, liver toxicity, dyslipidemia, and increasing cardiovascular events. Calof *et al.* (80) published a meta-analysis of adverse events in middle-aged and older men who have been treated with testosterone. They found that older men treated with testosterone had more prostate events and more erythrocytosis. In a recent meta-analysis of adverse events, Fernández-Balsells *et al.* (81) found that testosterone treatment was associated with a significant increase in hematocrit [3.18%; 95% confidence interval (CI), 1.35–5.01], hemoglobin (0.80 g/dl; 95% CI, 0.45–1.14), and a decrease in high-density lipoprotein (HDL) cholesterol (–0.49 mg/dl; 95% CI, –0.85 to –0.13). There was no significant effect on mortality, prostate, or cardiovascular outcomes. The Testosterone in Older Men with Mobility Limitations (TOM) trial was not included in either of these meta-analyses (82). This RPCT was discontinued early because 23 men in the testosterone group *vs.* five men in the placebo group, out of the 209 men who were enrolled in the trial, had cardiovascular-related adverse events. These men had a high prevalence of chronic disease, and the mean  $\pm$  SD testosterone levels were  $574 \pm 403$  and  $292 \pm 160$  ng/dl in the testosterone and placebo groups, respectively.

The greatest concerns about testosterone treatment are in older men. It is thought that the potential benefits are less certain and the potential risks are greater. There is concern that testosterone treatment may increase clinical prostate cancers and cardiovascular events. The latter concern has been lessened by epidemiological studies indicating that men with lower testosterone levels have increased cardiovascular events; however, the study by Basaria *et al.* (82) renews this issue.

### **Acne and male pattern baldness**

Testosterone therapy can increase secretion of sebum, cause acne, and accelerate male pattern baldness (83). Because these effects require metabolism of testosterone to dihydrotestosterone, it may be possible to minimize the effects by treatment with a 5- $\alpha$ -reductase inhibitor. Acne tends to be more common in younger males. Usually, it can be managed by good personal hygiene, an antiseptic soap, and topical retinoids, benzoyl peroxide, sulfacetamide, or azelaic acid (84).

### **Gynecomastia**

Gynecomastia at puberty is common in boys. Usually it regresses without treatment. It is thought to be due to an alteration in the free estrogen:free androgen ratio, although it is not possible to demonstrate this in many patients (85). Testosterone treatment can cause or worsen

gynecomastia in some men, but usually it does not require stopping treatment. If the gynecomastia is tender or painful, treatment with an antiestrogen such as tamoxifen can be beneficial (85).

### **Sleep apnea**

Sleep apnea is reported to cause low testosterone levels, and treatment of sleep apnea may increase testosterone levels (86, 87). Testosterone treatment with supraphysiological doses has been reported to cause or worsen sleep apnea, but evidence that replacement doses of testosterone cause sleep apnea is poor (88). Nonetheless, it is prudent to evaluate patients with symptoms suggesting sleep apnea before testosterone replacement. If they have sleep apnea, reassessment of testosterone levels after treatment of sleep apnea is suggested.

### **Prostate**

There are theoretical concerns that testosterone treatment of older men could increase clinical prostate cancer; however, available evidence is not convincing. The prostate is an androgen-responsive organ. It increases in size at puberty as testosterone levels increase, but it does not increase in size at puberty in males with 5- $\alpha$ -reductase deficiency or in individuals with androgen resistance (89–91). Testosterone replacement of younger, androgen-deficient males is associated with an increase in prostate volume, but only to that of normal, eugonadal men (92). Testosterone treatment can accelerate metastatic prostate cancer (93). Although androgen ablation causes temporary regression of metastatic prostate cancers and a 20–30% reduction in prostate volume of men with benign prostatic hyperplasia (94, 95), prostate cancer incidence and benign prostatic hyperplasia prevalence increase in older men when serum testosterone levels are falling (96–98). Furthermore, a rigorous analysis of all prospective epidemiological studies did not find a relationship between testosterone levels and future incidence of prostate cancer (99). Nonetheless, the prevalence of occult prostate cancer increases with age (100), and it is not known whether increasing the serum testosterone levels into the range observed in young normal men will increase the incidence of clinical prostate cancer.

The limited number of testosterone trials in older men have not reported an increase in clinical prostate cancer from what would be expected in this age group, but the man-years of exposure is too limited to assess risk (80, 81). We have estimated that it will take a 5-yr study in which 6000 hypogonadal men are randomized to testosterone or placebo to detect a 30% increase in clinical prostate cancer. Although short-term studies like The Testosterone Trial can strengthen or refute the potential benefits of tes-

tosterone treatment in older men, short-term studies are not powered to assess long-term potential risks of prostate cancer or cardiovascular disease. In the interim, a testosterone registry has been established in Europe. A registry will not obviate the need for a long-term safety study, but it can provide useful interim data that will help to assess the potential benefit:risk ratio for treating older men with testosterone.

### **Breast cancer**

A recent report found increased risk of breast cancer in men with Klinefelter's syndrome (relative risk = 16.83; 95% CI, 6.81–41.62) (101). Most breast cancers in men are estrogen receptor positive (102), and testosterone is partially metabolized to estradiol. Reports of breast cancers in men treated with testosterone are rare (103), but it is wise to examine the breasts before and during treatment.

### **Erythrocytosis**

In the meta-analysis of adverse events, testosterone-treated men were nearly four times more likely than placebo-treated men to have a hematocrit greater than 50% (odds ratio = 3.69; 95% CI, 1.82–7.51) (80, 81). Of the 35 testosterone-treated men in the first meta-analysis with a hematocrit greater than 50%, one patient had a cerebral hemorrhage. Higher hematocrits are associated with increased blood viscosity and decreased blood flow (104, 105). Higher hematocrits have been associated with increased myocardial infarctions, coronary insufficiency, and coronary heart disease deaths (106). More recent studies have associated carotid atherosclerosis, ischemic heart disease, and stroke with hematocrit and blood viscosity (107, 108). Therefore, careful monitoring of the hematocrit and hemoglobin during testosterone treatment is indicated.

### **Suppression of spermatogenesis**

Testosterone treatment will suppress gonadotropins and spermatogenesis (109, 110). Testosterone treatment is not appropriate for treatment of testosterone-deficient men who desire to father a child in the near future.

### **Cardiovascular**

Men have more cardiovascular events than women through age 74 (111). Initially, it was thought that either testosterone increased or estrogen decreased cardiovascular events. However, most epidemiological studies have found that men with lower testosterone levels are at increased risk for having cardiovascular events when compared with men with higher levels (112). Furthermore, treatment of postmenopausal women with estrogen increased rather than decreased cardiovascular events (113).

Although two meta-analyses have failed to find that testosterone treatment increases the risk of cardiovascular events (80, 81), one of the two studies in men 65 and older that was published in 2010 reported a significant increase in cardiovascular events (64, 82).

### **Liver toxicity**

Oral 17-alkylated testosterone derivatives have been associated with liver toxicity, and because of this they are not recommended for testosterone replacement treatment in men (14).

### **Lipids**

In the meta-analysis conducted on RPCT trials by Isidori *et al.* (72), there was a significant decrease in total cholesterol that was more pronounced in the group with lower testosterone levels. A reduction in HDL cholesterol was detectable only in studies with higher pretreatment testosterone concentrations. The effects on low-density lipoprotein cholesterol were not significant. Fernández-Balsells *et al.* (81) also noted a small but significant decrease in HDL cholesterol.

### **Treatment options**

We now have multiple testosterone delivery systems, and they vary in their pharmacokinetics and in their side effect profiles (Table 3). Oral testosterone undecanoate fails to maintain physiological levels of testosterone during the night, and outcome studies suggest that it is less effective (114, 115). Injectable testosterone cypionate and enanthate deliver supraphysiological levels of testosterone for the initial treatment period, and they seem to be more likely to cause erythrocytosis and perhaps sleep apnea (41, 82, 88, 116). Testosterone patches are likely to cause dermatological reactions (41). Topical application of transdermal gels can achieve physiological levels of testosterone in most men, but they leave a film of testosterone on the skin that can be transferred to a child or female (117). Subcutaneous testosterone pellets and intratestosterone undecanoate can provide physiological levels of testosterone for many weeks (118, 119), but this could be a disadvantage in men who develop erythrocytosis or a prostate issue. Cost of testosterone replacement therapy ranges from relatively inexpensive injections of generic testosterone cypionate or enanthate to expensive testosterone gels and long-acting delivery systems. Thus, pharmacokinetics, pharmacodynamics, side effects, and cost must be considered when choosing a specific delivery system for a given patient.

### **Monitoring Treatment**

Patients who choose testosterone replacement therapy must be monitored for effectiveness of treatment. One

**TABLE 3.** Advantages and disadvantages of testosterone formulations

Formulation	Regimen	Advantages	Disadvantages
T enanthate or cypionate	150–200 mg/2 wk im or 75–100 mg/wk im	Corrects symptoms of androgen deficiency; relatively inexpensive, if self-administered; flexibility of dosing.	Requires im injection; peaks and valleys in serum T levels.
1% T gel	Available in sachets, tubes and pumps; 5–10 g T gel containing 50–100 mg T should be applied daily.	Corrects symptoms of androgen deficiency; provides flexibility of dosing, ease of application, good skin tolerability.	Potential of transfer to a female partner or child by direct skin-to-skin contact; skin irritation in a small proportion of treated men; moderately high DHT levels.
Transdermal T patch	1 or 2 patches, designed to nominally deliver 5–10 mg T over 24 h; applied daily on nonpressure areas.	Ease of application, corrects symptoms of androgen deficiency.	Serum T levels in some androgen-deficient men may be in the low-normal range; these men may need application of 2 patches daily. Skin irritation at the application site occurs in many patients.
Buccal, bioadhesive T tablets	30-mg controlled release, bioadhesive tablets used twice daily.	Corrects symptoms of androgen deficiency in healthy, hypogonadal men.	Gum-related adverse events in 16% of treated men.
T pellets	Three to six pellets implanted sc; dose and regimen vary with formulation used.	Corrects symptoms of androgen deficiency.	Requires surgical incision for insertions; pellets may extrude spontaneously.
17- $\alpha$ -methyl T	This 17- $\alpha$ -alkylated compound should not be used because of potential for liver toxicity.		Clinical responses are variable; potential for liver toxicity. Should not be used for treatment of androgen deficiency in men.
Oral T undecanoate <sup>a</sup>	40 to 80 mg orally, 2 or 3 times daily with meals.	Convenience of oral administration.	Not approved in the United States. Variable clinical responses; variable serum T levels; high DHT:T ratio.
Injectable long-acting T undecanoate in oil <sup>b</sup>	The regimen used in Europe typically involves 1000 mg injected im, followed by 1000 mg at 6 wk, and 1000 mg every 10–14 wk	Corrects symptoms of androgen deficiency; requires infrequent administration.	Requires im injection of a large volume (4 ml). Cough has been reported immediately after injection in a very small number of treated men.
T-in-adhesive matrix patch <sup>c</sup>	2 $\times$ 60 cm <sup>2</sup> patches delivering approximately 4.8 mg of T/d	Lasts 2 d.	Some skin irritation.

Modified from The Endocrine Society Guidelines (14). T, Testosterone; DHT, dihydrotestosterone. Certain formulations are available in other countries but not in the United States. These include: <sup>a</sup> oral testosterone undecanoate (typically used at a dose of 40 to 80 mg orally two or three times daily with meals); <sup>b</sup> injectable testosterone undecanoate 1000 mg followed by a second 1000 mg injection 6 wk later, and then 1000 mg every 10 to 14 wk; and <sup>c</sup> two testosterone matrix patches 30, 45, or 60 cm<sup>2</sup> applied every 2 d.

would like to ensure that the patient is achieving physiological levels of testosterone. Usually, this is done within the first 1–2 months. Sampling time varies depending on the delivery system (Table 4). We try to achieve testosterone levels in the mid-normal (400–700 ng/dl) range for young men (14). One may choose to lower this range some in older men. Assessment of clinical responses should be made within 2–4 months of initiating treatment. Some symptoms such as libido, energy, and mood are improved within 1–3 months, whereas it usually takes longer to see changes in body composition and BMD. If erectile dys-

function persists, treatment with a phosphodiesterase type 5 inhibitor may be helpful (120). One also should recognize that organ systems respond differently to testosterone levels within the physiological range. Libido, erectile function, and mood seem to be improved with levels in the low normal range (121), whereas skeletal muscle responds in a dose-responsive manner in younger and older men (55). Demonstrable changes in BMD are dependent on dose and duration of treatment (72). Most clinicians evaluate treatment effectiveness by reassessing the patient's presenting symptoms and by physical examination.

**TABLE 4.** Monitoring of men receiving testosterone therapy

1. Evaluate the patient 3 to 6 months after treatment initiation and then annually to assess whether symptoms have responded to treatment and whether the patient is suffering from any adverse effects.
2. Monitor testosterone level 3 to 6 months after initiation of testosterone therapy:
  - Therapy should aim to raise serum testosterone level into the mid-normal range.
  - Injectable testosterone enanthate or cypionate: measure serum testosterone level midway between injections. If testosterone is  $>700$  ng/dl (24.5 nmol/liter) or  $<350$  ng/dl (12.3 nmol/liter), adjust dose or frequency.
  - Transdermal patches: assess testosterone level 3–12 h after application of the patch; adjust dose to achieve testosterone level in the mid-normal range.
  - Buccal testosterone bioadhesive tablet: assess level immediately before or after application of fresh system.
  - Transdermal gels: assess testosterone level any time after patient has been on treatment for at least 1 wk; adjust dose to achieve serum testosterone level in the mid-normal range.
  - Testosterone pellets: measure testosterone levels at the end of the dosing interval. Adjust the number of pellets and/or the dosing interval to achieve serum testosterone levels in the normal range.
  - Oral testosterone undecanoate: monitor serum testosterone level 3 to 5 h after ingestion.
  - Injectable testosterone undecanoate: Measure serum testosterone level just prior to each subsequent injection and adjust the dosing interval to maintain serum testosterone in mid-normal range.
3. Check hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit is  $>54\%$ , stop therapy until hematocrit decreases to a safe level; evaluate the patient for hypoxia and sleep apnea; reinstitute therapy with a reduced dose.
4. Measure BMD of lumbar spine and/or femoral neck after 1–2 yr of testosterone therapy in hypogonadal men with osteoporosis or low trauma fracture, consistent with regional standard of care.
5. In men 40 yr of age or older with baseline PSA greater than 0.6 ng/ml, perform digital rectal examination and check PSA level before initiating treatment, at 3 to 6 months, and then in accordance with guidelines for prostate cancer screening depending on the age and race of the patient.
6. Obtain urological consultation if there is:
  - An increase in serum PSA concentration  $>1.4$  ng/ml within any 12-month period of testosterone treatment.
  - A PSA velocity of  $>0.4$  ng/ml  $\cdot$  yr using the PSA level after 6 months of testosterone administration as the reference (only applicable if PSA data are available for a period exceeding 2 yr).
  - Detection of a prostatic abnormality on digital rectal examination.
  - An AUA/IPSS prostate symptom score of  $>19$ .

Modified from The Endocrine Society Guidelines (14).

Patients also must be evaluated for potential side effects associated with testosterone treatment and for those that are delivery system specific (Table 4). The frequency of monitoring and the parameters that should be monitored are dependent on age. Patients should be questioned about skin reactivity, and application sites should be monitored when patients are treated with transdermal delivery systems. Middle-aged and older men are at potential risk for developing or worsening of sleep apnea, so they and their mates should be questioned for symptoms of sleep apnea.

The American Urological Association Best Practice Statement (2009) recommends evaluation of a prostate-specific antigen (PSA) level and a digital rectal examination of the prostate at age 40 (<http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf>). Individuals with PSA levels above the median (0.6 ng/dl) for this age should be monitored annually, whereas monitoring can be less frequent for those below the median. When lower urinary tract symptoms are significant or when treatment is increasing male pattern baldness, one can consider using a 5- $\alpha$ -reductase inhibitor; however, trial data showing that this is effective in patients being treated with testosterone are limited.

## Conclusion

The diagnosis and treatment of androgen deficiency are less controversial in younger men with classical causes of androgen deficiency who have unequivocally low testosterone levels. The diagnosis is less certain in middle-aged and older men with comorbid diseases and borderline low testosterone levels. Clinical trials in these men have produced more equivocal outcomes. Several RPCTs in older testosterone-deficient men have shown improvement in outcomes. A large, multicenter, National Institute on Aging-sponsored study is under way. It should provide definitive answers to potential benefits of testosterone replacement in older men. However, it is not powered to assess potential risks of prostate cancer and cardiovascular events. For now, clinicians should discuss the available efficacy and risk data for testosterone replacement and should help each patient make the decision that is best for him.

## Acknowledgments

Address all correspondence and requests for reprints to: Glenn R. Cunningham, M.D., 6624 Fannin, Suite 1180, Houston, Texas 77030. E-mail: glennc@bcm.edu.

Disclosure Summary: G.R.C. received fees for consultation or advisement from Abbott/Solvay Pharmaceuticals, Clarus, Co-



lumbia Lab, GSK, and Indevus/Endo Pharmaceuticals; grant or other research support from Abbott/Solvay Pharmaceuticals, Columbia Lab, GSK, and Repros; is on the speaker's list of Abbott Pharmaceuticals, Columbia Lab, and Indevus/Endo Pharmaceuticals; and has a financial or business/organizational interest in UpToDate. S.M.T. has nothing to disclose.

## References

1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab* 86:724–731
2. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB 2002 Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 87:589–598
3. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D 2008 Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. *J Clin Endocrinol Metab* 93:2737–2745
4. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB 2007 Prevalence of symptomatic androgen deficiency in men. *J Clin Endocrinol Metab* 92:4241–4247
5. Litman HJ, Bhasin S, Link CL, Araujo AB, McKinlay JB 2006 Serum androgen levels in black, Hispanic, and white men. *J Clin Endocrinol Metab* 91:4326–4334
6. Ding EL, Song Y, Malik VS, Liu S 2006 Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 295:1288–1299
7. Laaksonen DE, Niskanen L, Punnonen K, Nyysönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. *Diabetes Care* 27:1036–1041
8. Laughlin GA, Barrett-Connor E, Bergstrom J 2008 Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab* 93:68–75
9. Khaw KT, Dowsett M, Folkard E, Bingham S, Wareham N, Luben R, Welch A, Day N 2007 Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation* 116:2694–2701
10. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, Metter EJ, Artoni A, Carassale L, Cazzato A, Ceresini G, Guralnik JM, Basaria S, Valenti G, Ferrucci L 2007 Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. *Arch Intern Med* 167:2249–2254
11. Menke A, Guallar E, Rohrmann S, Nelson WG, Rifai N, Kanarek N, Feinleib M, Michos ED, Dobs A, Platz EA 2010 Sex steroid hormone concentrations and risk of death in US men. *Am J Epidemiol* 171:583–592
12. Krasnoff JB, Basaria S, Pencina MJ, Jasuja GK, Vasan RS, Ulloor J, Zhang A, Coviello A, Kelly-Hayes M, D'Agostino RB, Wolf PA, Bhasin S, Murabito JM 2010 Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. *J Clin Endocrinol Metab* 95:2790–2799
13. Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, Yeap BB 2010 Low free testosterone predicts frailty in older men: the Health in Men Study. *J Clin Endocrinol Metab* 95:3165–3172
14. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM 2010 Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 95:2536–2559
15. Zitzmann M, Faber S, Nieschlag E 2006 Association of specific symptoms and metabolic risks with serum testosterone in older men. *J Clin Endocrinol Metab* 91:4335–4343
16. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT 2010 Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med* 363:123–135
17. Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, Morgentaler A, Miner MM 2009 Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls. *Aging Male* 12:77–85
18. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB 2009 The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. *J Clin Endocrinol Metab* 94:907–913
19. Bremner WJ, Vitiello MV, Prinz PN 1983 Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. *J Clin Endocrinol Metab* 56:1278–1281
20. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H 2007 Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society Position Statement. *J Clin Endocrinol Metab* 92:405–413
21. Vesper HW, Bhasin S, Wang C, Tai SS, Dodge LA, Singh RJ, Nelson J, Ohorodnik S, Clarke NJ, Salameh WA, Parker Jr CR, Razdan R, Monsell EA, Myers GL 2009 Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. *Steroids* 74:498–503
22. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* 84:3666–3672
23. Manni A, Partridge WM, Cefalu W, Nisula BC, Bardin CW, Santner SJ, Santen RJ 1985 Bioavailability of albumin-bound testosterone. *J Clin Endocrinol Metab* 61:705–710
24. de Ronde W, van der Schouw YT, Pols HA, Gooren LJ, Muller M, Grobbee DE, de Jong FH 2006 Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. *Clin Chem* 52:1777–1784
25. Citron JT, Ettinger B, Rubinoff H, Ettinger VM, Minkoff J, Hom F, Kan P, Alloo R 1996 Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. *J Urol* 155:529–533
26. Handelsman DJ, Liu PY 2006 Klinefelter's syndrome—a microcosm of male reproductive health. *J Clin Endocrinol Metab* 91:1220–1222
27. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E 2004 Klinefelter's syndrome. *Lancet* 364:273–283
28. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E 2003 Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? *Int J Impot Res* 15:156–165
29. Strain GW, Zumoff B, Miller LK, Rosner W, Levit C, Kalin M, Hershcovf RJ, Rosenfeld RS 1988 Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. *J Clin Endocrinol Metab* 66:1019–1023
30. Bastounis EA, Karayiannakis AJ, Syrigos K, Zbar A, Makri GG, Alexiou D 1998 Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. *Eur Surg Res* 30:43–47
31. Vermeulen A 2005 Hormonal cut-offs of partial androgen defi-



- ciency: a survey of androgen assays. *J Endocrinol Invest* 28(3 Suppl):28–31
32. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad Jr JG, Strom BL 1999 Effect of testosterone treatment on bone mineral density in men over 65 years of age. *J Clin Endocrinol Metab* 84:1966–1972
  33. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL 1999 Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab* 84:2647–2653
  34. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT 2008 Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. *JAMA* 299:39–52
  35. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE 2003 Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. *J Gerontol A Biol Sci Med Sci* 58:618–625
  36. Blackman MR, Sorkin JD, Münzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, Harman SM 2002 Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. *JAMA* 288:2282–2292
  37. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC 2009 ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. *Aging Male* 12:5–12
  38. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. *J Clin Endocrinol Metab* 85:2839–2853
  39. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA 2003 A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. *BJU Int* 91:69–74
  40. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N 2001 Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. *Clin Endocrinol (Oxf)* 54:739–750
  41. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA 1999 Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. *J Clin Endocrinol Metab* 84:3469–3478
  42. Saad F, Gooren LJ, Haider A, Yassin A 2008 A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. *J Androl* 29:102–105
  43. Richmond EJ, Rogol AD 2007 Male pubertal development and the role of androgen therapy. *Nat Clin Pract Endocrinol Metab* 3:338–344
  44. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A 1992 Osteopenia in men with a history of delayed puberty. *N Engl J Med* 326:600–604
  45. Drobac S, Rubin K, Rogol AD, Rosenfield RL 2006 A workshop on pubertal hormone replacement options in the United States. *J Pediatr Endocrinol Metab* 19:55–64
  46. Gordon D, Lauder JC, Cohen HN, O'Donnell AM, Semple CG, Thomson JA 1990 An evaluation of human chorionic gonadotrophin (HCG) therapy in boys with delayed puberty. *Q J Med* 74:247–256
  47. Soliman AT, Nasr I, Thabet A, Rizk MM, El Matary W 2005 Human chorionic gonadotropin therapy in adolescent boys with constitutional delayed puberty vs those with  $\beta$ -thalassemia major. *Metabolism* 54:15–23
  48. Delemarre-van de Waal HA 2004 Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism—diagnostic and therapeutic aspects. *Eur J Endocrinol* 151(Suppl 3):U89–U94
  49. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL 2000 Effects of testosterone replacement in hypogonadal men. *J Clin Endocrinol Metab* 85:2670–2677
  50. Kirk JM, Trainer PJ, Majrowski WH, Murphy J, Savage MO, Besser GM 1994 Treatment with GHRH(1–29)NH<sub>2</sub> in children with idiopathic short stature induces a sustained increase in growth velocity. *Clin Endocrinol (Oxf)* 41:487–493
  51. Kung AW, Zhong YY, Lam KS, Wang C 1994 Induction of spermatogenesis with gonadotrophins in Chinese men with hypogonadotropic hypogonadism. *Int J Androl* 17:241–247
  52. Whitten SJ, Nangia AK, Kolettis PN 2006 Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. *Fertil Steril* 86:1664–1668
  53. Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, Dzekov J, Bhasin S 2008 Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. *J Am Geriatr Soc* 56:1991–1999
  54. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S 2006 Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. *J Clin Endocrinol Metab* 91:3024–3033
  55. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW 2005 Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. *J Clin Endocrinol Metab* 90:678–688
  56. Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, Dzekov C, Sinha-Hikim I, Bhasin S 2005 Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. *J Clin Endocrinol Metab* 90:3838–3846
  57. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, Kawakubo M, Stewart Y, Yarasheski KE, Ulloor J, Colletti P, Roubenoff R, Azen SP 2009 Testosterone and growth hormone improve body composition and muscle performance in older men. *J Clin Endocrinol Metab* 94:1991–2001
  58. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A 2005 Effects of testosterone on sexual function in men: results of a meta-analysis. *Clin Endocrinol (Oxf)* 63:381–394
  59. Bolaña ER, Uruga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM 2007 Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. *Mayo Clin Proc* 82:20–28
  60. Zarrouf FA, Artz S, Griffith J, Sirbu C, Komor M 2009 Testosterone and depression: systematic review and meta-analysis. *J Psychiatr Pract* 15:289–305
  61. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G 2004 Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. *Urology* 63:641–646
  62. Srinivas-Shankar U, Sharma D 2009 Testosterone treatment in elderly men. *Adv Ther* 26:25–39
  63. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S 2004 Effects of testosterone on behavior, depression, and cognitive func-

- tion in older men with mild cognitive loss. *J Gerontol A Biol Sci Med Sci* 59:75–78
64. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC 2010 Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab* 95:639–650
  65. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM 2009 A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). *J Clin Psychiatry* 70:1009–1016
  66. Tan RS, Pu SJ 2003 A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. *Aging Male* 6:13–17
  67. Janowsky JS, Oviatt SK, Orwoll ES 1994 Testosterone influences spatial cognition in older men. *Behav Neurosci* 108:325–332
  68. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, Hines M 1998 Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. *Horm Behav* 33:85–94
  69. Janowsky JS, Chavez B, Orwoll E 2000 Sex steroids modify working memory. *J Cogn Neurosci* 12:407–414
  70. Sih R, Morley JE, Kaiser FE, Perry 3rd HM, Patrick P, Ross C 1997 Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. *J Clin Endocrinol Metab* 82:1661–1667
  71. Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G 2002 Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci* 57:M460–M465
  72. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A 2005 Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. *Clin Endocrinol (Oxf)* 63:280–293
  73. Boyanov MA, Boneva Z, Christov VG 2003 Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. *Aging Male* 6:1–7
  74. Kapoor D, Goodwin E, Channer KS, Jones TH 2006 Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. *Eur J Endocrinol* 154:899–906
  75. Heufelder AE, Saad F, Bunck MC, Gooren L 2009 Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. *J Androl* 30:726–733
  76. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES 2006 Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. *J Clin Endocrinol Metab* 91:3908–3915
  77. Tracz MJ, Sideras K, Boloña ER, Haddad RM, Kennedy CC, Uruga MV, Caples SM, Erwin PJ, Montori VM 2006 Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. *J Clin Endocrinol Metab* 91:2011–2016
  78. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG 2001 Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci* 56:M266–M272
  79. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2004 Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. *J Clin Endocrinol Metab* 89:503–510
  80. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S 2005 Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. *J Gerontol A Biol Sci Med Sci* 60:1451–1457
  81. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM 2010 Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 95:2560–2575
  82. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ullor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S 2010 Adverse events associated with testosterone administration. *N Engl J Med* 363:109–122
  83. Deplewski D, Rosenfield RL 2000 Role of hormones in pilosebaceous unit development. *Endocr Rev* 21:363–392
  84. Feldman S, Careccia RE, Barham KL, Hancox J 2004 Diagnosis and treatment of acne. *Am Fam Physician* 69:2123–2130
  85. Braunstein GD 2007 Clinical practice. Gynecomastia. *N Engl J Med* 357:1229–1237
  86. Santamaria JD, Prior JC, Fleetham JA 1988 Reversible reproductive dysfunction in men with obstructive sleep apnoea. *Clin Endocrinol (Oxf)* 28:461–470
  87. Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Cateron ID, Sullivan CE 1989 Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. *J Clin Endocrinol Metab* 68:352–358
  88. Hanafy HM 2007 Testosterone therapy and obstructive sleep apnea: is there a real connection? *J Sex Med* 4:1241–1246
  89. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, Ramirez de Arellano E, Kazam E 1992 Prostate visualization studies in males homozygous and heterozygous for 5  $\alpha$ -reductase deficiency. *J Clin Endocrinol Metab* 75:1022–1026
  90. Brinkmann AO, Jenster G, Ris-Stalpers C, van der Korput JA, Brüggewirth HT, Boehmer AL, Trapman J 1995 Androgen receptor mutations. *J Steroid Biochem Mol Biol* 53:443–448
  91. Salmasi AH, Wisniewski AB, Novak TE, Gearhart JP, Migeon CJ, Lakshmanan Y 2008 Prostate screening in patients with 46,XY disorders of sex development—is it necessary? *J Urol* 180:1422–1425; discussion 1425–1426
  92. Behre HM, Bohmeyer J, Nieschlag E 1994 Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. *Clin Endocrinol (Oxf)* 40:341–349
  93. Fowler Jr JE, Whitmore Jr WF 1981 The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. *J Urol* 126:372–375
  94. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. *N Engl J Med* 321:419–424
  95. Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M 1998 Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. *J Clin Endocrinol Metab* 83:3826–3831
  96. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer statistics, 2009. *CA Cancer J Clin* 59:225–249
  97. Berry SJ, Coffey DS, Walsh PC, Ewing LL 1984 The development of human benign prostatic hyperplasia with age. *J Urol* 132:474–479
  98. Jacobsen SJ, Girman CJ, Lieber MM 2001 Natural history of benign prostatic hyperplasia. *Urology* 58(6 Suppl 1):5–16; discussion 16
  99. Roddam AW, Allen NE, Appleby P, Key TJ 2008 Endogenous sex

- hormones and prostate cancer: a collaborative analysis of 18 prospective studies. *J Natl Cancer Inst* 100:170–183
100. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP 1994 High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. *In Vivo* 8:439–443
  101. Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G 2010 Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. *Breast Cancer Res Treat* 119:185–192
  102. Fentiman IS, Fourquet A, Hortobagyi GN 2006 Male breast cancer. *Lancet* 367:595–604
  103. Thomas SR, Evans PJ, Holland PA, Biswas M 2008 Invasive breast cancer after initiation of testosterone replacement therapy in a man—a warning to endocrinologists. *Endocr Pract* 14:201–203
  104. Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM 1991 Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. *J Urol* 146:1566–1570
  105. Semple PD, Lowe GD, Patterson J, Beastall GH, Rowan JO, Forbes CD, Hume R 1983 Comparison of cerebral blood flow after venesection of bronchitic secondary polycythaemic and primary polycythaemic patients. *Scott Med J* 28:332–337
  106. Sorlie PD, Garcia-Palmieri MR, Costas Jr R, Havlik RJ 1981 Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. *Am Heart J* 101:456–461
  107. Irace C, Ciamei M, Crivaro A, Fiaschi E, Madia A, Cortese C, Gnasso A 2003 Hematocrit is associated with carotid atherosclerosis in men but not in women. *Coron Artery Dis* 14:279–284
  108. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG 1997 Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. *Br J Haematol* 96:168–173
  109. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, Bo L, Xiong C, Wang X, Liu X, Peng L, Yao K 2009 Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. *J Clin Endocrinol Metab* 94:1910–1915
  110. Amory JK 2006 Male hormonal contraceptives. *Minerva Ginecol* 58:215–226
  111. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y 2009 Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 119:480–486
  112. Liu PY, Death AK, Handelsman DJ 2003 Androgens and cardiovascular disease. *Endocr Rev* 24:313–340
  113. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R 2006 Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. *Arch Intern Med* 166:357–365
  114. Jungwirth A, Plas E, Geurts P 2007 Clinical experience with Andriol Testocaps—the first Austrian surveillance study on the treatment of late-onset hypogonadism. *Aging Male* 10:183–187
  115. Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloix PM 2009 Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. *Eur J Endocrinol* 160:821–831
  116. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S 2008 Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. *J Clin Endocrinol Metab* 93:914–919
  117. de Ronde W 2009 Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. *Hum Reprod* 24:425–428
  118. Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E 2007 More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. *Asian J Androl* 9:291–297
  119. Handelsman DJ, Conway AJ, Boylan LM 1990 Pharmacokinetics and pharmacodynamics of testosterone pellets in man. *J Clin Endocrinol Metab* 71:216–222
  120. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H 2004 Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. *J Urol* 172:658–663
  121. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response relationships in healthy young men. *Am J Physiol Endocrinol Metab* 281:E1172–E1181
  122. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R 2003 AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab* 88:2673–2681
  123. Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F, Ross RJ 2006 Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. *Int J Androl* 29:381–391
  124. Brockenbrough AT, Ditttrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ 2006 Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. *Am J Kidney Dis* 47:251–262
  125. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS 2006 Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. *JAMA* 296:2351–2361
  126. Chiang HS, Cho SL, Lin YC, Hwang TI 2009 Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. *Urology* 73:762–766
  127. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2005 Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. *J Clin Endocrinol Metab* 90:1502–1510
  128. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton 3rd LJ, Smith GE, Khosla S, Jensen MD 2006 DHEA in elderly women and DHEA or testosterone in elderly men. *N Engl J Med* 355:1647–1659
  129. Vaughan C, Goldstein FC, Tenover JL 2007 Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. *J Androl* 28:875–882
  130. Agledahl I, Hansen JB, Svartberg J 2008 Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. *Scand J Clin Lab Invest* 68:641–648
  131. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galván R 2008 Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. *Aging Male* 11:140–145
  132. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R 2008 Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. *Int J Impot Res* 20:378–387
  133. Agledahl I, Brodin E, Svartberg J, Hansen JB 2009 Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. *Thromb Haemost* 102:945–950